NCT03720561 (EVIdeNCE) is a clinical trial of Ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Janssen-Cilag S.p.A..

Who is sponsoring NCT03720561?

NCT03720561 is sponsored by Janssen-Cilag S.p.A..

What drugs are being tested in NCT03720561?

Interventions in NCT03720561: Ibrutinib.

What condition does NCT03720561 study?

NCT03720561 studies Leukemia, Lymphocytic, Chronic, B-Cell.

Is NCT03720561 still recruiting?

NCT03720561 is currently completed. Last updated 3 January 2022.

Last reviewed 2022-01-03 · How we verify

NCT03720561: EVIdeNCE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting

Completed Last updated 3 January 2022

What this trial tests

trial testing Ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell in 312 participants. Completed in 12 November 2021.

Timeline

30 October 2018

Primary endpoint
12 November 2021

12 November 2021

Quick facts

Lead sponsor	Janssen-Cilag S.p.A.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	312
Start date	30 October 2018
Primary completion	12 November 2021
Estimated completion	12 November 2021
Sites	39 locations across Italy

Drugs / interventions tested

Ibrutinib (ibrutinib) — full drug profile →

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell — all drugs for Leukemia, Lymphocytic, Chronic, B-Cell →

Sponsor

Janssen-Cilag S.p.A. — full company profile →

Who can join

18 and older, any sex, with Leukemia, Lymphocytic, Chronic, B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to describe the 2-year retention rate of ibrutinib treatment for chronic lymphocytic leukemia (CLL) in Italian routine clinical practice.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR, Scalzulli PR, Scarfò L, Minoia C, et al · · 2024 · cited 8× · PMID 38539561 · DOI 10.3390/cancers16061228
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.
Molica S, Scalzulli PR, Scarfò L, Minoia C, et al · · 2026 · PMID 41899601 · DOI 10.3390/cancers18061000

Verify or expand the search:

Other trials of Ibrutinib

Trials testing the same drug.

NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
NCT07052695 — Mosunetuzumab for CLL MRD Clearance · Phase 1, PHASE2 · recruiting
NCT06649812 — Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress · Phase 2 · recruiting
NCT07169565 — Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia · Phase 1 · not yet recruiting
NCT06357676 — Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · Phase 1, PHASE2 · recruiting

Other recruiting trials for Leukemia, Lymphocytic, Chronic, B-Cell

Currently open trials in the same condition.

NCT06364423 — Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias · Phase 1, PHASE2 · recruiting
NCT05963074 — A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemi · Phase 2 · recruiting
NCT06299540 — Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lym · recruiting
NCT05947851 — A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) · Phase 3 · recruiting
NCT05424822 — A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin · Phase 1 · active not recruiting

Other Janssen-Cilag S.p.A. trials

Trials by the same sponsor.

NCT04567602 — A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag · completed
NCT04463108 — A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With I · completed
NCT04439526 — A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis · completed
NCT03577470 — An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and T · completed
NCT03131661 — A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targete · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03720561 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag S.p.A.
Last refreshed: 3 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03720561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing